

August 12, 2021

Rochelle Walensky, MD, PhD
Director
U.S. Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329

Dear Dr. Walensky:

We are writing on behalf of the 34 million Americans living with diabetes to respectfully request consideration as your agency develops guidance on prioritizing certain populations for booster doses of the COVID-19 vaccine. Specifically, we urge your agency to consider the disproportionately negative health impact and outcomes COVID-19 has on people with diabetes and, as a result, release guidance prioritizing those with the disease to receive protection provided by booster doses of the vaccine.

Thus far, we understand that the agency has focused its attention on immunocompromised populations for additional doses of the vaccine. This approach correctly identifies those individuals who are more susceptible to contracting COVID-19; however, it may neglect a wide population of patients who suffer disproportionately poor outcomes after contracting COVID-19, including those Americans living with diabetes and/or cardiovascular disease, many of whom also have obesity.

As you know, people with diabetes suffer some of the worst health consequences from the COVID-19 virus, including:

- [Forty percent](#) of COVID-19-related fatalities in America have been in people with diabetes;
- Americans with diabetes and other related underlying health conditions are hospitalized [6 times more often](#) and are 12 times more likely to die from COVID-19 than those without an underlying condition;
- Other than cardiovascular disease, diabetes is the [most commonly reported underlying health condition](#) among U.S. COVID patients; and
- [Ten percent](#) of people with diabetes die within seven days of a COVID-related hospitalization.

Because of these circumstances – and the disproportionately poor health outcomes from COVID-19 in people with diabetes – we respectfully request the guidance promulgated by your agency include consideration for people with diabetes. Specifically, our hope is that you will include people with diabetes in your recommendations for those Americans who are eligible for booster vaccine doses.

Again, on behalf of the 34 million Americans living with diabetes, we appreciate your consideration of these comments and we look forward to working with you and your agency to help inform your guidance. If you have any questions, please do not hesitate to contact Chris Fox, Senior Vice President, External Affairs at cfox@diabetes.org.

Sincerely,

Robert Gabbay, MD, PhD, FACP
Chief Science and Medical Officer
American Diabetes Association

Leslie E. Kolb, RN, BSN, MBA
Chief Science, Practice and Learning Officer
Association of Diabetes Care & Education Specialists

Michael R. Duenas, OD, FNAP
Chief Public Health Officer
American Optometric Association

Sanjoy Dutta, PhD
Vice President, Research
JDRF

Christel Marchand Aprigliano, MS
Chief Advocacy Officer
Beyond Type 1

Jeff Hitchcock
President
Children with Diabetes

Christina Roth
Chief Executive Officer and Founder
College Diabetes Network

R. Stewart Perry
Board Chair
Diabetes Leadership Council

George Huntley
Chief Executive Officer
Diabetes Patient Advocacy Coalition

Anna Norton, MS
Chief Executive Officer
DiabetesSisters

James R. Christina, DPM
Chief Executive Officer
American Podiatric Medical Association

Tammy Boyd, JD, MPH
Chief Policy Officer and Counsel
Black Women's Health Imperative

Sharon Oberfield, MD
President
Pediatric Endocrine Society

Jim Carroll
Chief Executive Officer
The diaTribe Foundation

Katie Adamson
Vice President, Health Partnerships and Policy
YMCA of the USA

CC: Dr. Grace Lee, Chair, CDC Advisory Committee on Immunization Practices (ACIP)
Dr. Amanda Cohn, Executive Secretary CDC Advisory Committee on Immunization Practices (ACIP)